ST Renfu: HW091077 tablets enter Phase II clinical trial

ST Renfu announces that its wholly owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., recently published the registration information for Phase II clinical trials of HW091077 tablets on the National Medical Products Administration’s Drug Clinical Trial Registration and Information Disclosure Platform.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin